Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer

References

• Athauda G, Giubellino A, Coleman JA, et al. (2006). c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 12:4154–62
   Google Scholar
• Bean J, Brennan C, Shih JY, et al. (2007). Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932–7
   PubMed Web of Science ®Google Scholar
• Christensen JG, Burrows J, Salgia R. (2005). c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225:1–26
   PubMed Web of Science ®Google Scholar
• Cooper CS, Park M, Blair DG, et al. (1984). Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29–33
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007). Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–43
   PubMed Web of Science ®Google Scholar
• Galvani AP, Cristiani C, Carpinelli P, et al. (1995). Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form. Biochem Pharmacol 50:959–66
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. (2012). Targeting MET in cancer: rationale and progress. Nature 12:89–103
   Google Scholar
• Glordano S, Di Renzo MF, Narsimban RP, et al. (1989). Biosynthesis of the protein encoded by the c-Met pro-oncogene. Oncogene 4:1383–8
   Google Scholar
• Huh CG, Factor VM, Sanchez A, et al. (2004). Hepatocyte growth factor/c-Met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101:4477–82
   PubMed Web of Science ®Google Scholar
• Klotz M, Schmid E, Steiner-Hahn K, et al. (2012). Preclinical evaluation of biomarkers for response monitoring to the Met inhibitors BAY-853474. Biomarkers (Early online) 4:1–11
   Google Scholar
• Kobayashi N, Aragane N, Nakamura T, et al. (2012). Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma [abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 31 Mar–4 Apr 2012; Chicago, IL. Philadelphia (PA): AACR Abstract nr 1737
   Google Scholar
• Kosaka T, Yatabe Y, Endoh H, et al. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12:5764–9
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl J Med 350:2129–39
   PubMed Web of Science ®Google Scholar
• Marissa NB, Yixuan G, Gregory JR, et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Cancer Lett 12:6494–501
   Google Scholar
• McDermott U, Sharma SV, Dowell L, et al. (2007). Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104:19936–41
   PubMed Web of Science ®Google Scholar
• Nakamura T, Mizuno S, Matsumoto K, et al. (2000). Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106:1511–19
   PubMed Web of Science ®Google Scholar
• Nath D, Williamson N, Jarvis R, Murphy G. (2001). Shedding of c-Met is regulated by crosstalk between a G protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 114:1213–20
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–500
   PubMed Web of Science ®Google Scholar
• Park S, Choi YL, Sung CO, et al. (2012). High Met copy number and Met overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 27:197–207
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. (2006). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:3657–60
   PubMed Web of Science ®Google Scholar
• Prat M, Crepaldi T, Gandino L, et al. (1991). C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 11:5954–62
   PubMed Web of Science ®Google Scholar
• Puri N, Salgia R. (2008). Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinogenesis 7:9–17
   Google Scholar
• Rosell R, Moran T, Queralt C, et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–67
   PubMed Web of Science ®Google Scholar
• Sorbellini M, Mcneil B, Cohen B, et al. (2011). Urinary Met level as a novel biomarker for urothelial carcinoma of the bladder. J Clin Oncol 29:2011 (suppl 7; abstr 257) (poster in 2011 Genitourinary Cancer Symposium)
   Google Scholar
• Travis WD, Brambilla E, Muller-Hermlink HK. (2004). World Health Organization classification of tumors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press
   Google Scholar
• Wader KF, Fagerli UM, Holt RU, et al. (2011). Soluble c-Met in serum of patients with multiple myeloma correlation with clinical parameters. Eur J Haematol 87:394–9
   PubMed Web of Science ®Google Scholar
• Wen PY, Schiff D, Cloughesy TF, et al. (2010). A phase 2 study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int 108:679–86
   Google Scholar
• Yu W, Pandita A, Penuel E, et al. (2011a). Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29:2011 (suppl; abstr 7505) ( poster and presentation in 2011 ASCO Annual Meeting)
   Google Scholar
• Yu W, Pandita A, Penuel E, et al. (2011b). Exploratory biomarker analyses from OAM4558g: a placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC), J Clin Oncol 29: 2011 (suppl; abstr 7529) (poster in 2011 ASCO Annual Meeting)
   Google Scholar